Fate Therapeutics
Fate Therapeutics operates advanced manufacturing facilities in San Diego for iPSC-derived cell therapies and collaborates with several institutions to develop cancer treatments.
Manufacturing Facilities
Fate Therapeutics operates two cGMP-compliant manufacturing facilities for the clinical production of iPSC-derived cell product candidates in San Diego, California. These facilities have been issued drug manufacturing licenses by the State of California, Department of Health Services, Food and Drug Branch. In 2022, the company extended its manufacturing capabilities to a new corporate headquarters to support all phases of clinical development and initial commercialization.
Pipeline of iPSC-Derived NK Cell Product Candidates
Fate Therapeutics is developing a pipeline of iPSC-derived NK cell product candidates aimed at treating cancer. These product candidates leverage induced pluripotent stem cell technology to potentially offer effective and scalable cancer immunotherapy solutions.
Collaborations in Cancer Treatment
Fate Therapeutics is engaged in multiple collaborations to advance cancer treatment. The company is working with ONO Pharmaceutical to develop and commercialize off-the-shelf CAR-T cell product candidates targeting solid tumors. Additional research collaborations include partnerships with the University of Minnesota on iPSC-derived CAR NK cell cancer immunotherapies, Memorial Sloan Kettering Cancer Center for iPSC-derived T-cell immunotherapies, and Oslo University Hospital focusing on NK cell biology and killer cell immunoglobulin-like receptors.
Intellectual Property Portfolio
Fate Therapeutics holds a substantial intellectual property portfolio comprising over 400 issued patents and 450 pending patent applications related to iPSC technology. This extensive IP portfolio underscores the company's innovative contributions to the field and supports its various product and research initiatives.